Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001668

Methotrexate for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Methotrexate, (+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N10-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H22N8O5
Numéro CAS:
59-05-2
Poids moléculaire :
454.44
Numéro Beilstein :
70669
Numéro MDL:
MFCD00064370
Code UNSPSC :
41116107
ID de substance PubChem :
329831530
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

methotrexate

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

Clé InChI

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Informations sur le gène

human ... DHFR(1719)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methotrexate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

M1000000

Methotrexate, European Pharmacopoeia (EP) Reference Standard

M1000008

Methotrexate impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000602

Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000663

Methotrexate impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000664

Methotrexate impurity E, European Pharmacopoeia (EP) Reference Standard

PHR1396

Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material

1414003

Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413988

R-Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413999

Methotrexate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1414025

Methotrexate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1414036

Methotrexate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1414058

Methotrexate Related Compound E, United States Pharmacopeia (USP) Reference Standard

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H341,H360D,H372

Classification des risques

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

Organes cibles

Liver,Bone marrow

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Methotrexate solution 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-136

Methotrexate solution

Méthotrexate hydrate powder, BioReagent, suitable for cell culture, ≥98% (HPLC)

Sigma-Aldrich

M8407

Méthotrexate hydrate

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Giovanni L Mancardi et al.
Neurology, 84(10), 981-988 (2015-02-13)
To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary
Rongrong Jiang et al.
British journal of pharmacology, 172(4), 1059-1073 (2014-10-10)
Ginsenosides are bioactive saponins derived from Panax notoginseng roots (Sanqi) and ginseng. Here, the molecular mechanisms governing differential pharmacokinetics of 20(S)-protopanaxatriol-type ginsenoside Rg1 , ginsenoside Re and notoginsenoside R1 and 20(S)-protopanaxadiol-type ginsenosides Rb1, Rc and Rd were elucidated. Interactions of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique